SG10201503407WA - Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors - Google Patents

Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Info

Publication number
SG10201503407WA
SG10201503407WA SG10201503407WA SG10201503407WA SG10201503407WA SG 10201503407W A SG10201503407W A SG 10201503407WA SG 10201503407W A SG10201503407W A SG 10201503407WA SG 10201503407W A SG10201503407W A SG 10201503407WA SG 10201503407W A SG10201503407W A SG 10201503407WA
Authority
SG
Singapore
Prior art keywords
vegf
adjuvant
treatment
early stage
specific antagonists
Prior art date
Application number
SG10201503407WA
Inventor
Napoleone Ferrara
Nina Korsisaari
Robert D Mass
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201503407WA publication Critical patent/SG10201503407WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
SG10201503407WA 2006-12-19 2007-12-18 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors SG10201503407WA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US87074506P 2006-12-19 2006-12-19
US87074106P 2006-12-19 2006-12-19
US87726706P 2006-12-27 2006-12-27
US91963807P 2007-03-22 2007-03-22
US95838407P 2007-07-05 2007-07-05
US98939707P 2007-11-20 2007-11-20

Publications (1)

Publication Number Publication Date
SG10201503407WA true SG10201503407WA (en) 2015-06-29

Family

ID=39323719

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201503407WA SG10201503407WA (en) 2006-12-19 2007-12-18 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
SG2011080801A SG176448A1 (en) 2006-12-19 2007-12-18 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011080801A SG176448A1 (en) 2006-12-19 2007-12-18 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Country Status (28)

Country Link
US (6) US20080248033A1 (en)
EP (2) EP3095455A1 (en)
JP (4) JP2010513566A (en)
KR (5) KR20090097188A (en)
CN (1) CN103143017A (en)
AR (1) AR064458A1 (en)
AU (1) AU2007333735A1 (en)
BR (1) BRPI0720552A2 (en)
CA (1) CA2671734A1 (en)
CO (1) CO6210829A2 (en)
CR (1) CR10940A (en)
DK (1) DK2101807T3 (en)
EC (1) ECSP099523A (en)
ES (1) ES2582656T3 (en)
HK (1) HK1133210A1 (en)
HU (1) HUE029445T2 (en)
IL (1) IL238913A0 (en)
MA (1) MA31150B1 (en)
MX (1) MX2009006779A (en)
MY (1) MY183404A (en)
NO (1) NO20092604L (en)
NZ (1) NZ578472A (en)
PL (1) PL2101807T3 (en)
RU (1) RU2013129450A (en)
SG (2) SG10201503407WA (en)
SI (1) SI2101807T1 (en)
TW (2) TWI577695B (en)
WO (1) WO2008077077A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2066694T1 (en) 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AR069501A1 (en) * 2007-11-30 2010-01-27 Genentech Inc ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP6041489B2 (en) * 2008-11-22 2016-12-07 ジェネンテック， インコーポレイテッド Use of anti-VEGF antibodies in combination with chemotherapy for the treatment of breast cancer
EP2393513B1 (en) * 2009-02-06 2016-10-19 The General Hospital Corporation Methods of treating vascular lesions
JP5501439B2 (en) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト Multispecific antibody comprising a full-length antibody and a single chain Fab fragment
KR101456326B1 (en) 2009-04-07 2014-11-12 로슈 글리카트 아게 Trivalent, bispecific antibodies
US20100266589A1 (en) * 2009-04-20 2010-10-21 Eric Hedrick Adjuvant cancer therapy
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN104945509A (en) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
WO2011094722A1 (en) 2010-02-01 2011-08-04 Cedars-Sinai Medical Center Use of tyrosine kinase inhibitors for treatment of cushing's disease and hypercortisolism
WO2011094716A1 (en) * 2010-02-01 2011-08-04 Cedars-Sinai Medical Center Use of tyrosine kinase inhibitors for treatment of prolactinoma
MX360640B (en) 2010-03-01 2018-11-09 Tau Therapeutics Llc Star Cancer diagnosis and imaging.
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
KR20130091746A (en) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibodies comprising disulfide-stabilized Fv fragments
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2681240B1 (en) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalent antigen binding proteins
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
US20140219999A1 (en) * 2011-04-01 2014-08-07 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
EP2704745B1 (en) 2011-05-05 2016-12-14 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
CN103857699B (en) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 Multivalence and unit price polyspecific complex and application thereof
WO2013039859A1 (en) * 2011-09-12 2013-03-21 Gray Lloyd S Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
HUE042192T2 (en) 2011-09-23 2019-06-28 Oncomed Pharm Inc Vegf/dll4 binding agents and uses thereof
WO2013085973A1 (en) * 2011-12-05 2013-06-13 Subhransu Ray Treatment for angiogenic disorders
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2639287C2 (en) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Method for selection and obtaining of highly selective and multispecific targeting groups with specified properties, including at least two different binding groups, and their applications
JP6154900B2 (en) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト Bispecific anti-VEGF / anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
JP6371294B2 (en) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with DLL4 antagonists
EP2925887B1 (en) 2012-12-03 2018-03-07 Koninklijke Philips N.V. Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
WO2015052230A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
ES2764111T3 (en) 2014-12-03 2020-06-02 Hoffmann La Roche Multispecific antibodies
JP6967003B2 (en) 2015-09-23 2021-11-17 メレオ バイオファーマ ５ インコーポレイテッド Methods and compositions for the treatment of cancer
CA3009813A1 (en) * 2015-12-30 2017-07-06 Visiongate, Inc. System and method for automated detection and monitoring of dysplasia and administration of chemoprevention
WO2017201166A1 (en) * 2016-05-17 2017-11-23 Duke University Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer
BR112020012336A2 (en) 2017-12-19 2021-03-30 Akouos, Inc. ADMINISTRATION OF AAV MEDIATED THERAPEUTIC ANTIBODIES FOR INTERNAL EAR
US11026649B2 (en) * 2018-06-25 2021-06-08 Siemens Medical Solutions Usa, Inc. Method and system for determining tumor burden in medical images
SG11202107334RA (en) * 2019-02-18 2021-08-30 Agency Science Tech & Res A membrane-bound fit-1 decoy and uses thereof
TW202110431A (en) * 2019-05-17 2021-03-16 美商癌症預防製藥股份有限公司 Methods for treating familial adenomatous polyposis
CN112773852A (en) * 2021-03-16 2021-05-11 宁夏医科大学 Preparation process of Chinese herbal medicine composition with cell protection effect
CN113512589B (en) * 2021-07-14 2023-03-10 复旦大学附属中山医院 Application of PRUNE1 gene detection in prognosis of multiple myeloma patients

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ES2259800T3 (en) 1990-06-11 2006-10-16 Gilead Sciences, Inc. PROCEDURES FOR THE USE OF NUCLEIC ACID LINKS.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE297465T1 (en) 1991-11-25 2005-06-15 Enzon Inc METHOD FOR PRODUCING MULTIVALENT ANTIGEN-BINDING PROTEINS
ATE348110T1 (en) 1992-10-28 2007-01-15 Genentech Inc HVEGF RECEPTOR AS A VEGF ANTAGONIST
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1997033551A2 (en) 1996-03-15 1997-09-18 Millennium Pharmaceuticals Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
PT1787999E (en) 1997-04-07 2010-11-11 Genentech Inc Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69829891T2 (en) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF antibody
US20030114407A1 (en) 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
ES2694002T3 (en) 1999-01-15 2018-12-17 Genentech, Inc. Polypeptide comprising an Fc region of variant human IgG1
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2001072587A (en) * 1999-07-01 2001-03-21 Taisho Pharmaceut Co Ltd Vegf receptor antagonist
ATE428719T1 (en) 1999-07-29 2009-05-15 Gilead Sciences Inc NUCLEIC ACID LIGANDS FOR HEPATOCYTIC GROWTH FACTOR/DISPERSION FACTOR (HGF/SF) AND ITS C-MET RECEPTOR
JP2003518075A (en) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド Methods and compositions for extending the elimination half-life of bioactive compounds
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
ES2649037T3 (en) 2000-12-12 2018-01-09 Medimmune, Llc Molecules with prolonged half-lives, compositions and uses thereof
ME00425B (en) * 2003-05-30 2011-10-10 Genentech Inc Treatment with anti-vegf antibodies
PL1636593T3 (en) 2003-06-06 2009-08-31 Genentech Inc Modulating the interaction between hgf beta chain and c-met
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20050044853A1 (en) * 2003-09-02 2005-03-03 Kazutora Yoshino Ecology system
CN101102786A (en) * 2004-06-10 2008-01-09 瑞泽恩制药公司 Method of administering and using VEGF inhibitors for the treatment of human cancer
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
BRPI0513534A (en) * 2004-07-20 2008-05-06 Genentech Inc angiopoietin-like protein 4 inhibitors, combinations, and their use

Also Published As

Publication number Publication date
KR20140148491A (en) 2014-12-31
JP2013189452A (en) 2013-09-26
AU2007333735A1 (en) 2008-06-26
MY183404A (en) 2021-02-18
RU2013129450A (en) 2015-01-10
US20140178363A1 (en) 2014-06-26
EP2101807B1 (en) 2016-05-25
DK2101807T3 (en) 2016-08-29
US20110052576A1 (en) 2011-03-03
JP2010513566A (en) 2010-04-30
WO2008077077A2 (en) 2008-06-26
EP2101807A2 (en) 2009-09-23
AR064458A1 (en) 2009-04-01
US20080248033A1 (en) 2008-10-09
US20160108116A1 (en) 2016-04-21
TW200831538A (en) 2008-08-01
EP3095455A1 (en) 2016-11-23
ECSP099523A (en) 2009-09-29
US20180208647A1 (en) 2018-07-26
HUE029445T2 (en) 2017-02-28
AU2007333735A2 (en) 2009-11-05
CN103143017A (en) 2013-06-12
HK1133210A1 (en) 2010-03-19
SI2101807T1 (en) 2016-08-31
CA2671734A1 (en) 2008-06-26
CO6210829A2 (en) 2010-10-20
SG176448A1 (en) 2011-12-29
NZ578472A (en) 2012-06-29
KR20090097188A (en) 2009-09-15
KR20140031996A (en) 2014-03-13
CR10940A (en) 2009-08-13
WO2008077077A3 (en) 2008-08-14
KR20130060309A (en) 2013-06-07
JP2018052939A (en) 2018-04-05
BRPI0720552A2 (en) 2014-01-07
TW201525003A (en) 2015-07-01
JP2015110609A (en) 2015-06-18
MX2009006779A (en) 2009-08-27
MA31150B1 (en) 2010-02-01
US20120148584A1 (en) 2012-06-14
IL238913A0 (en) 2015-06-30
TWI577695B (en) 2017-04-11
KR20150097813A (en) 2015-08-26
ES2582656T3 (en) 2016-09-14
NO20092604L (en) 2009-09-18
PL2101807T3 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IL238913A0 (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
IL248204A0 (en) Combination treatment of cd38-expressing tumors
GB0504988D0 (en) Device and method for the treatment of diseased tissue such as tumors
EP1985302A4 (en) Medicament for treatment of tumor and the use thereof
GB0700560D0 (en) Device and method for the treatment of diseased tissue such as tumours
EP1814909A4 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
EP2211913A4 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
EP1994181A4 (en) Identification and use of novopeptides for the treatment of cancer
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL227841A0 (en) Dihydropteridinones for the treatment of cancer diseases
EP2212440A4 (en) Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
EP1971278A4 (en) Device for superficial abrasive treatment of the skin
IL188430A0 (en) Treatment of tumors
IL193747A0 (en) New therapeutic combinations for the treatment of depression
EP2049139A4 (en) Treatment of ras-expressing tumors
EP2046973A4 (en) For the identification, assessment, and treatment of patients with cancer therapy
GB0604471D0 (en) Device and method for the treatment of tumours
PL2056842T3 (en) Modified-galactosyl ceramide for the treatment of cancerous diseases
PT2101731T (en) Endoxifen for use in the treatment of cancer
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
EP2029156A4 (en) Combination therapy for treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1737475A4 (en) Herbal therapy for the treatment of asthma
IL226363A0 (en) Compounds and methods for the treatment of cancer
EP1797430A4 (en) Methods and compositions for the diagnosis and treatment of cancer